

Exhibit I

	CUSTODIAN	DUPLICATE CUSTODIANS	FROM	TO	CC	SUBJECT	DATE SENT	FILENAME	DOCUMENT DATE	DATE CREATED	DOCUMENT TYPE	BASIS FOR REDACTION	DESCRIPTION
1	GE_Jucai	CHEN_Baozhen GE_Jucai LIN_Lihong	Jun Du <jun.du88@gmail.com>	Linda Lin <lindalin@huahaipharm.com>	gejucai <gejucai@huahaipharm.com> 陈宝珍 <chenbaozhen@huahaipharm.com>	Re: FDA 483 +欧盟检查缺陷以及答复概要	12/15/2018	Re_FDA 483 +欧盟检查缺陷以及答复概要.eml	12/15/2018	5/21/2020	RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	An email of ZHP, discussing the materials prepared to send to national and provincial medical products administrations.
2	GE_Jucai	CHEN_Baozhen GE_Jucai LIN_Lihong	lindalin@huahaipharm.com	Jun Du <jun.du88@gmail.com>	gejucai <gejucai@huahaipharm.com> 陈宝珍 <chenbaozhen@huahaipharm.com>	Re: Re: FDA 483 +欧盟检查缺陷以及答复概要	12/16/2018	Re_Re_FDA 483 +欧盟检查缺陷以及答复概要 (1).eml	12/16/2018	5/21/2020	RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	An email discussing the materials prepared to send to national and provincial medical products administrations.
3	GE_Jucai	CHEN_Baozhen GE_Jucai LIN_Lihong	lindalin@huahaipharm.com	Jun Du <jun.du88@gmail.com>	gejucai <gejucai@huahaipharm.com> 陈宝珍 <chenbaozhen@huahaipharm.com>	Re: Re: FDA 483 +欧盟检查缺陷以及答复概要	12/17/2018	Re_Re_FDA 483 +欧盟检查缺陷以及答复概要.eml	12/17/2018	5/21/2020	RFC822 Email Message	Arts. 2, 9 and 48 of the Law of the People's Republic of China on Protecting State Secrets. Arts. 2, 10, 16 and 17 of the Regulations of the People's Republic of China on the Disclosure of Government Information.	An email discussing the materials prepared to send to national and provincial medical products administrations.